Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Influenza Drug Market Heading Into 2029?

The market size of influenza medication has experienced robust growth in the recent past. The projection is that its growth will escalate from $0.98 billion in 2024 to $1.04 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.4%. The past growth rate can be linked to frequent outbreaks of seasonal flu, an increase in healthcare spending, rising awareness about vaccines, wider use of antiviral drugs, and the enhancement of government immunization agendas.

The market size for influenza medication is anticipated to experience significant growth in the upcoming years, expected to reach $1.32 billion in 2029, with a compound annual growth rate (CAGR) of 6.0%. This projected expansion during the forecast period is due to the rising incidence of influenza-like conditions, improved global access to healthcare, the development of healthcare infrastructure in developing economies, increased demand for combination treatments, and an amplified focus on preventive healthcare. The forecast period will also witness major trends such as innovation in creating vaccines, advancements in diagnostic abilities, the emergence of next-generation antiviral medications, progress in antiviral research, and improvements in drug delivery systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27317&type=smp

Which Factors Are Pushing The Influenza Drug Market Forward?

The escalating prevalence of influenza infections is projected to boost the expansion of the influenza drug market. Influenza infections are infectious respiratory diseases triggered by influenza viruses, resulting in symptoms like fever, cough, sore throat, and body aches. The frequent viral mutations diminish the effectiveness of vaccines and increase people’s susceptibility to outbreaks, leading to the rise in influenza infections. Influenza drugs work to prevent this escalation by offering effective treatments that can lower the severity of the disease and manage widespread transmission. For example, data from the Centers for Disease Control and Prevention (CDC), a prominent public health agency based in the US, from September 2023 shows that preliminary in-season estimates for the 2022–2023 season reveal the impact of influenza virus infections in the US, causing 31 million symptomatic illnesses, 14 million medical visits, 360,000 hospitalizations, and 21,000 deaths. Hence, the escalating prevalence of influenza infections is fueling the expansion of the influenza drug market.

Which Segment Held The Largest Share In The Influenza Drug Market In 2025?

The influenza drug market covered in this report is segmented

1) By Type: Influenza A, Influenza B, Influenza C

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Route Of Administration: Oral, Intranasal, Intravenous, Intramuscular, Subcutaneous

4) By Mechanism Of Action: Neuraminidase Inhibitors, Cap-Dependent Endonuclease Inhibitors, Fusion Inhibitors, M2 Ion Channel Inhibitors, Host Cell Protease Inhibitors, Immunomodulatory Agents, Ribonucleic Acid (RNA) Polymerase Inhibitors, Hemagglutinin Stem Binders, Cytokine Inhibitors, Host Factor Targeting

5) By End-User: Hospitals And Clinics, Pharmacies, Vaccination Centers, Research Institutions, Government Health Agencies, Long-Term Care Facilities, Community Health Centers, Corporate Health Programs

How Are Key Trends Driving Expansion In The Influenza Drug Industry?

In the influenza drug market, leading companies are concentrating on advancements in technology, such as drug formulation, to improve the effectiveness of treatments, patient adherence, and overall therapeutic results. Drug formulation often entails the combination of inert substances and excipients with active pharmaceutical ingredients (APIs) to create functional drug products with desired characteristics. For example, F. Hoffmann-La Roche Ltd., a Swiss company specializing in pharmaceuticals and diagnostics, launched a strawberry-flavored, single-dose oral antiviral called Baloxavir Marboxil for Suspension in August 2024. It’s designed for children and allows parents to ensure correct weight-based dosing, thus aiding in easy administration and adherence. This innovation presents an accurate home-based medication delivery alternative, falling in line with the trend of prescription delivery services, by enabling caregivers to efficiently manage pediatric influenza treatment at home following a prescription. Its strengths lie in the unique specificity of its mechanism and improved adherence, although resistance may develop, particularly among pediatric patients, over time.

Which Organizations Are Driving Progress In The Influenza Drug Industry?

Major companies operating in the influenza drug market are F. Hoffmann-La Roche Ltd., Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Moderna Inc., BioNTech SE, Shionogi & Co. Ltd., Green Cross Corp, Emergent BioSolutions Inc., Novavax Inc., Hualan Biological Engineering Inc., Serum Institute of India Pvt. Ltd., CSL Seqirus Pty Ltd., BioCryst Pharmaceuticals, Inc., SAB Biotherapeutics Inc., Viriom Inc., Osivax SAS, Cocrystal Pharma Inc., Sinovac Biotech Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/influenza-drug-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Influenza Drug Industry?

North America was the largest region in the influenza drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=27317&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model